Skip to main content

Susan Kay Murphy, PhD

Property title
Associate Professor in Obstetrics and Gynecology
Campus Mail: 119 B Wing LSRC, 308 Research Drive, Durham, NC 27708
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

Ovarian and cervical cancer epigenetics, imprinted genes in ovarian and cervical cancers, identification of methylation biomarkers of disease, ovarian cancer stem cells, chemotherapeutic response in ovarian cancer, tumor dormancy, the influence of the in utero environment on DNA methylation and risk of disease.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina at Charlotte, 1992

Selected Grants and Awards

Publications

Kondoh, E., T. Baba, N. Malsumura, I. Konishi, S. Fujii, A. Berchuck, and S. K. Murphy. “7-hydroxystaurosporine (UCN-01) is effective in targeting ovarian cancer spheroids.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S161–62.

Scholars@Duke

Yamaguchi, K., M. Mandai, N. Matsumura, T. Baba, T. Oura, S. Matsui, S. K. Murphy, A. Berchuck, S. Fujii, and I. Konishi. “Gene signature specific for ovarian clear cell carcinoma is induced by the contents of endometriotic cysts.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S132–S132.

Scholars@Duke

Barnett, J. C., E. Kondoh, R. Whitaker, S. K. Murphy, and A. Berchuck. “High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S107–S107.

Scholars@Duke

Murphy, S. K., and L. Chen. “Imprinted Neuronatin: A potential epigenetie biomarker of ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S135–S135.

Scholars@Duke

Horne, Hisani N., Paula S. Lee, Susan K. Murphy, Miguel A. Alonso, John A. Olson, and Jeffrey R. Marks. “Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy..” Mol Cancer Res 7, no. 2 (February 2009): 199–209. https://doi.org/10.1158/1541-7786.MCR-08-0314.

Full Text

Murphy, S. K., Z. Huang, Y. Wen, L. R. Simel, T. M. Price, and A. Berchuck. “Intragenic methylation at a novel CTCF binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S138–S138.

Scholars@Duke

Baba, T., H. S. Kang, N. Matsumura, J. Hamanishi, M. Mandai, A. Berchuck, S. K. Murphy, and I. Konishi. “Loss of GPR54 correlates with stem cell activity in high-grade endometrial cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S78–S78.

Scholars@Duke

Resnick, K. E., H. Alder, A Alvarez Secord, R. Whitaker, D. L. Richardson, C. Heaphy, S. K. Murphy, T. Baba, C. Croce, and D. E. Colin. “MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S115–16.

Scholars@Duke

Barnett, J. C., R. Whitaker, E. Kondoh, T. Baba, S. K. Murphy, and A. Berchuck. “Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S11–S11.

Scholars@Duke

Barnett, J. C., E. Iverson, H. Dressman, R. Whitaker, S. K. Murphy, J. Lancaster, and A. Berchuck. “Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S123–24.

Scholars@Duke

Pages